Home/Pipeline/Mazindol ER (NLS-4)

Mazindol ER (NLS-4)

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2CompletedNCT04163926

Key Facts

Indication

Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase

Phase 2

Status

Completed

Company

NLS Pharmaceutics

About NLS Pharmaceutics

NLS Pharmaceutics is a clinical-stage biotech focused on developing improved therapeutics for CNS disorders, particularly narcolepsy. Its core strategy involves the repurposing and reformulation of known pharmacologic agents to enhance efficacy, duration, and tolerability. The company's lead asset, Mazindol ER (NLS-4/Quilience®), has demonstrated promising Phase 2 results for narcolepsy and is advancing into a pivotal Phase 3 program. Operating as a lean, virtual organization, NLS aims to efficiently navigate clinical development and address high-value market opportunities with limited treatment options.

View full company profile

Therapeutic Areas

Central Nervous System (CNS)Sleep-Wake Disorders

Other Attention-Deficit/Hyperactivity Disorder (ADHD) Drugs

Drug	Company	Phase	Status
ADHD Portfolio (e.g., Karbinal™ ER)	Aytu BioPharma	Commercial	Marketed
CTx-1301	Cingulate Therapeutics	Phase 3	Active, Pivotal Trials Completed Enrollment
CTx-1302	Cingulate Therapeutics	Phase 3	Planned
Botanically-derived Compound(s)	ABVC BioPharma	Phase II	Active